Myasthenia Gravis Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

• In 2022, there will be more than 700,000 prevalent cases of MG across 16 pharmaceutical markets.
• There are five marketed innovator drugs for the treatment of MG, mostly protein/peptide inhibitors and receptor antagonists.
• Among the pipeline molecules for MG, one is in pre-registration and 12 molecules are in Phase III development.
• Commercial sponsors dominate clinical trial development in MG, with the Netherlands emerging as the key country for conducting Phase III trials in MG.
• During the past 12 months, two strategic alliances and one merger and acquisition transaction involving MG assets were successfully completed.
• Emerging players in the MG treatment space are focused on launching novel investigational drugs for the treatment on a global scale.

Scope

Components of the report include:

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Retail or Manufacturer Price of Products
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Myasthenia Gravis market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Myasthenia Gravis market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.